LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 1045

Search options

  1. Article: Ebastine in the Treatment of Allergic Rhinitis and Urticaria: 30 Years of Clinical Studies and Real-World Experience.

    Sastre, J

    Journal of investigational allergology & clinical immunology

    2019  Volume 30, Issue 3, Page(s) 156–168

    Abstract: Histamine, acting predominantly via the H1-receptor, is an important mediator of the symptoms of allergy. H1-antihistamines, which stabilize the receptor in its inactive form, are the treatment of choice for some chronic allergic conditions. Ebastine is ... ...

    Abstract Histamine, acting predominantly via the H1-receptor, is an important mediator of the symptoms of allergy. H1-antihistamines, which stabilize the receptor in its inactive form, are the treatment of choice for some chronic allergic conditions. Ebastine is a well-established secondgeneration oral H1-antihistamine that is administered once daily at a dose of 10-20 mg and is available both as a standard tablet and as a fast-dissolving tablet that disintegrates in the mouth. Ebastine has been shown to relieve symptoms in patients with allergic rhinitis or urticaria in multiple clinical trials. In addition to its antihistamine effects, the drug has modulating effects on the allergic inflammatory process, thus potentially explaining its beneficial effect on nasal obstruction in some patients. Ebastine is generally well tolerated at recommended doses and is one of the lowest-risk antihistamines with respect to adverse cognitive/psychomotor effects, as confirmed by decades of pharmacovigilance. New long-term data confirm its efficacy and tolerability during up to 1 year of treatment in patients with chronic urticaria.
    MeSH term(s) Administration, Oral ; Butyrophenones/therapeutic use ; Histamine/metabolism ; Histamine H1 Antagonists/therapeutic use ; Humans ; Piperidines/therapeutic use ; Rhinitis, Allergic/drug therapy ; Treatment Outcome ; Urticaria/drug therapy
    Chemical Substances Butyrophenones ; Histamine H1 Antagonists ; Piperidines ; Histamine (820484N8I3) ; ebastine (TQD7Q784P1)
    Language English
    Publishing date 2019-04-12
    Publishing country Spain
    Document type Journal Article ; Review
    ZDB-ID 1128657-x
    ISSN 1018-9068
    ISSN 1018-9068
    DOI 10.18176/jiaci.0401
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3487: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Reply to Liccardi et al.

    Sastre, J

    Journal of investigational allergology & clinical immunology

    2016  Volume 26, Issue 6, Page(s) 406

    Language English
    Publishing date 2016
    Publishing country Spain
    Document type Letter ; Comment
    ZDB-ID 1128657-x
    ISSN 1018-9068
    ISSN 1018-9068
    DOI 10.18176/jiaci.0106
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3487: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Effect of different therapeutic strategies on olfactory outcomes in patients with chronic rhinosinusitis with nasal polyps: a systematic review.

    Alobid, I / Barroso, B / Calvo, C / Ferrario, M G / Sastre, J

    Journal of investigational allergology & clinical immunology

    2024  

    Abstract: Introduction: Olfactory impairment is one of the cardinal symptoms of chronic rhinosinusitis with nasal polyps (CRSwNP), yet the effect of the currently available therapeutic options on the recovery of the sense of smell is not well defined. The aim of ... ...

    Abstract Introduction: Olfactory impairment is one of the cardinal symptoms of chronic rhinosinusitis with nasal polyps (CRSwNP), yet the effect of the currently available therapeutic options on the recovery of the sense of smell is not well defined. The aim of this systematic review was to compile the evidence on the impact of medical, surgical, and biological therapies on the olfactory outcomes in patients with CRSwNP.
    Methods: This review was conducted by two reviewers, according to the Preferred Reporting Items for Systematic Reviews and meta-Analyses (PRISMA) guidelines. The quality of evidence of all studies included in the qualitative synthesis was evaluated using the Critical Appraisal Skills Programme (CASP).
    Results: Forty-four studies were included in the qualitative synthesis (assessing sinonasal surgery [n = 23], biologics [n =15], and conventional medical treatment [n = 6]); most had moderate-to-high methodological quality. Overall, significant improvements in the sense of smell were detected with all analyzed interventions measured by either an objective or a subjective tool (or both). However, most studies used different outcome measurements, hindering comparisons between interventions, and data on clinically relevant changes were missing.
    Conclusion: Oral corticosteroids, biologics and sinonasal surgery improve olfactory impairment associated with CRSwNP, but the high variability among existing studies does not allow accurate comparisons.
    Language English
    Publishing date 2024-01-03
    Publishing country Spain
    Document type Journal Article ; Review
    ZDB-ID 1128657-x
    ISSN 1018-9068
    ISSN 1018-9068
    DOI 10.18176/jiaci.0987
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3487: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: The Discrepant Role of Fractional Exhaled Nitric Oxide in SARS-CoV-2 Infection.

    Betancor, D / Olaguibel, J M / Sastre, J

    Journal of investigational allergology & clinical immunology

    2022  Volume 32, Issue 5, Page(s) 417–418

    MeSH term(s) Breath Tests ; COVID-19 ; Exhalation ; Fractional Exhaled Nitric Oxide Testing ; Humans ; Nitric Oxide ; SARS-CoV-2
    Chemical Substances Nitric Oxide (31C4KY9ESH)
    Language English
    Publishing date 2022-10-03
    Publishing country Spain
    Document type Letter ; Comment
    ZDB-ID 1128657-x
    ISSN 1018-9068
    ISSN 1018-9068
    DOI 10.18176/jiaci.0842
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3487: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Reply to "Should measurements of exhaled nitric oxide before and after specific inhalation test with occupational allergens be performed?"

    Betancor, Diana / Sastre, Joaquin

    The journal of allergy and clinical immunology. In practice

    2022  Volume 10, Issue 3, Page(s) 888–889

    MeSH term(s) Allergens ; Breath Tests ; Exhalation ; Humans ; Nitric Oxide
    Chemical Substances Allergens ; Nitric Oxide (31C4KY9ESH)
    Language English
    Publishing date 2022-03-10
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 2843237-X
    ISSN 2213-2201 ; 2213-2198
    ISSN (online) 2213-2201
    ISSN 2213-2198
    DOI 10.1016/j.jaip.2021.12.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7086: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Eosinophilia Induced by Blocking the IL-4/IL-13 Pathway: Potential Mechanisms and Clinical Outcomes.

    Olaguibel, J M / Sastre, J / Rodríguez, J M / Del Pozo, V

    Journal of investigational allergology & clinical immunology

    2022  Volume 32, Issue 3, Page(s) 165–180

    Abstract: Five biological drugs are currently marketed for treatment of uncontrolled severe asthma. They all block type 2 inflammatory pathways by targeting IgE (omalizumab), the IL-5 pathway (mepolizumab, reslizumab, benralizumab), or the IL-4/IL-13 pathway ( ... ...

    Abstract Five biological drugs are currently marketed for treatment of uncontrolled severe asthma. They all block type 2 inflammatory pathways by targeting IgE (omalizumab), the IL-5 pathway (mepolizumab, reslizumab, benralizumab), or the IL-4/IL-13 pathway (dupilumab). Hypereosinophilia has been observed in 4%-25% of patients treated with dupilumab and is transient in most cases, although there have been reports of persistent cases of symptomatic hypereosinophilia consistent with eosinophilic granulomatosis with polyangiitis (EGPA), eosinophilic pneumonia, eosinophilic vasculitis, and sudden worsening of asthma symptoms. Cases of EGPA have been reported with all biologics, including anti-IL-5 agents, and with leukotriene receptor antagonists in publications or in the EudraVigilance database. In many cases, EGPA appears during tapering of systemic corticosteroids or after switching from an anti-IL-5 biologic to dupilumab, suggesting that systemic corticosteroids or the anti-IL-5 agent were masking vasculitis. This review investigates plausible mechanisms of dupilumab-induced hypereosinophilia and review cases of symptomatic hypereosinophilia associated with dupilumab. Blockade of the IL-4/IL-13 pathway reduces eosinophil migration and accumulation of blood by inhibiting eotaxin-3, VCAM-1, and TARC without simultaneously inhibiting eosinophilopoiesis in bone marrow. When choosing the optimal biologic, it seems necessary to consider the presence of hypereosinophilia (>1500/μL), in which case an anti-IL-5/IL-5R agent is preferable. Furthermore, when switching from an anti-IL-5/5R to an anti-IL-4/13R agent, blood eosinophils and clinical progress should be closely monitored. Nevertheless, dual therapy with anti-IL-5/5R and anti-IL4/IL-13R agents may be needed for optimal control, since both the IL-5 and the IL-4/IL-13 pathways can simultaneously contribute to airway inflammation. This approach can prevent the development of EGPA and other types of symptomatic hypereosinophilia while maintaining control of nasal polyposis. In the near future, it will be possible to use a new generation of biological therapies for the treatment of severe asthma. These act at a higher level of the inflammatory cascade, as is the case of the antialarmins tezepelumab and itepekimab.
    MeSH term(s) Adrenal Cortex Hormones/therapeutic use ; Asthma/drug therapy ; Churg-Strauss Syndrome/diagnosis ; Eosinophilia/drug therapy ; Granulomatosis with Polyangiitis/diagnosis ; Humans ; Interleukin-13 ; Interleukin-4 ; Interleukin-5
    Chemical Substances Adrenal Cortex Hormones ; Interleukin-13 ; Interleukin-5 ; Interleukin-4 (207137-56-2)
    Language English
    Publishing date 2022-05-06
    Publishing country Spain
    Document type Journal Article ; Review
    ZDB-ID 1128657-x
    ISSN 1018-9068
    ISSN 1018-9068
    DOI 10.18176/jiaci.0823
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3487: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Subcutaneous Immunotherapy With High-Dose Cat and Dog Extracts: A Real-life Study.

    Uriarte, S A / Sastre, J

    Journal of investigational allergology & clinical immunology

    2019  Volume 30, Issue 3, Page(s) 169–174

    Abstract: Background and objective: Background: Data on the efficacy of immunotherapy administered to patients with cat or dog allergy are scarce. Objective: We aimed to evaluate the safety and efficacy of subcutaneous immunotherapy (SCIT) in patients with ... ...

    Abstract Background and objective: Background: Data on the efficacy of immunotherapy administered to patients with cat or dog allergy are scarce. Objective: We aimed to evaluate the safety and efficacy of subcutaneous immunotherapy (SCIT) in patients with allergy to cat and dog dander.
    Methods: Consecutive patients with rhinitis and/or asthma related to sensitization to cat or dog dander were included in a pragmatic, real-life, prospective, observational study. All patients had specific IgE to cat, dog, or both. SCIT was administered using an infusion pump over 3 sessions as part of a rush protocol, followed by monthly administration over 12 months. We recorded adverse events, clinical outcomes, pulmonary function, FeNO, symptoms of rhinitis and asthma, quality of life (QoL), Asthma Control Test (ACT) score, and visual analog scale (VAS) score at baseline, 6 months, and 12 months.
    Results: The study population comprised 66 patients (38 females, 46 allergic to cat and 20 to dog), with ages ranging from 9 to 59 years. During the up-dosing phase, in which the infusion pump was used, 8.1% of doses elicited a systemic reaction and 5.4% caused a local reaction, while 9.3% of doses administered during the maintenance phase (ie, without an infusion pump) induced a systemic reaction. No local reactions were recorded. A significant improvement in FEV1, symptoms of rhinitis and asthma, QoL, use of medication, VAS score, and ACT score was observed at 6 months and continued at 12 months. Clinical improvement with cat extract was significantly better than with dog extract.
    Conclusions: High-dose SCIT has substantial clinical value in many cat- and dog-allergic patients.
    MeSH term(s) Adolescent ; Adult ; Animals ; Asthma/immunology ; Asthma/therapy ; Cats ; Child ; Complex Mixtures/immunology ; Desensitization, Immunologic/methods ; Dogs ; Female ; Humans ; Hypersensitivity/immunology ; Hypersensitivity/therapy ; Immunoglobulin E/blood ; Infusions, Subcutaneous ; Male ; Middle Aged ; Treatment Outcome ; Young Adult
    Chemical Substances Complex Mixtures ; Immunoglobulin E (37341-29-0)
    Language English
    Publishing date 2019-05-27
    Publishing country Spain
    Document type Journal Article
    ZDB-ID 1128657-x
    ISSN 1018-9068
    ISSN 1018-9068
    DOI 10.18176/jiaci.0415
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3487: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: Non-asthmatic eosinophilic bronquitis review. A systematic review of current treatment options.

    Betancor, D / Valverde-Monge, M / Barroso, B / Gomez-Lopez, A / Sastre, J

    Journal of investigational allergology & clinical immunology

    2023  

    Language English
    Publishing date 2023-12-19
    Publishing country Spain
    Document type Journal Article ; Review
    ZDB-ID 1128657-x
    ISSN 1018-9068
    ISSN 1018-9068
    DOI 10.18176/jiaci.0984
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3487: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: The Influence of BMI in Asthma: Which Traits Are due to Obesity and Which to the Asthma and Obesity Phenotype?

    Esteban-Gorgojo, I / Gorgojo, M P / Sastre, J / García-Río, F / Quirce, S

    Journal of investigational allergology & clinical immunology

    2023  Volume 34, Issue 1, Page(s) 30–37

    Abstract: Background and objectives: The characteristics of the asthma and obesity phenotype have been described in cluster studies but have not been subsequently confirmed. Specific characteristics of this phenotype have not been differentiated from those ... ...

    Abstract Background and objectives: The characteristics of the asthma and obesity phenotype have been described in cluster studies but have not been subsequently confirmed. Specific characteristics of this phenotype have not been differentiated from those inherent to the patient's body mass index (BMI). This study aims to assess the effect of BMI on asthma in order to identify which traits could define the asthma and obesity phenotype and which are inherent to the patient´s BMI.
    Methods: A real-life retrospective observational study was conducted based on data from 2514 patients with suspected asthma collected at the first visit to the allergy clinic between November 2014 and November 2017. All patients had to perform an appropriate spirometry maneuver. All BMI, sex, and age groups were represented.
    Results: The influence of BMI on asthma differed according to age group and sex. All spirometry results and FeNO were influenced by BMI. The only notable asthma characteristics were later onset of asthma with higher BMI values. No other differences were found between the BMI groups.
    Conclusions: The effect of BMI on asthma is age-dependent; therefore, it should be corrected for age. The most important variations are in FeNO and spirometry results. The specific characteristics of the asthma and obesity phenotype are a greater perception of symptoms with fewer alterations in respiratory function tests and a lower prevalence of atopy, rhinitis, and allergy, including allergic asthma. Other characteristics of this phenotype, such as a higher female prevalence or late-onset or noneosinophilic asthma, are nonspecific for this phenotype.
    MeSH term(s) Humans ; Female ; Body Mass Index ; Asthma/diagnosis ; Asthma/epidemiology ; Obesity/epidemiology ; Hypersensitivity ; Phenotype
    Language English
    Publishing date 2023-10-06
    Publishing country Spain
    Document type Observational Study ; Journal Article
    ZDB-ID 1128657-x
    ISSN 1018-9068
    ISSN 1018-9068
    DOI 10.18176/jiaci.0865
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3487: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Hypersensitivity Reactions to the GLP-1 Receptor Agonists Liraglutide and Semaglutide: A Case Series.

    Barroso, B / Gómez-López, A / Valverde-Monge, M / Betancor, D / de Las Heras, M / Sastre, J

    Journal of investigational allergology & clinical immunology

    2024  Volume 34, Issue 2, Page(s) 133–135

    MeSH term(s) Humans ; Glucagon-Like Peptide-1 Receptor Agonists/adverse effects ; Hypoglycemic Agents/adverse effects ; Liraglutide/adverse effects ; Drug Hypersensitivity
    Chemical Substances Glucagon-Like Peptide-1 Receptor Agonists ; Hypoglycemic Agents ; Liraglutide (839I73S42A) ; semaglutide (53AXN4NNHX)
    Language English
    Publishing date 2024-04-19
    Publishing country Spain
    Document type Case Reports ; Journal Article
    ZDB-ID 1128657-x
    ISSN 1018-9068
    ISSN 1018-9068
    DOI 10.18176/jiaci.0932
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3487: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top